Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide
- 1 November 2001
- journal article
- clinical trial
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 17 (6), 467-473
- https://doi.org/10.1002/dmrr.235
Abstract
Background Severe hypoglycaemia is a potentially life‐threatening condition. The aim of the present study was to compare the frequency of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Methods This prospective, population‐based, 4‐year study examined the incidence of severe hypoglycaemia in a region of Germany with 200 000 inhabitants. The blood glucose of all 30 768 patients who attended the emergency department of the region's central hospital was determined to detect severe hypoglycaemia, which was defined by the requirement for intravenous glucose or glucagon injection and blood glucose value of <2.8 mmol/l. Additionally, 6631/7804 patients (85%) attended to by the emergency medical services received a blood glucose test at the emergency site. The regional prescribing frequency of both sulphonylureas was determined by an independent external institute. Results Despite glimepiride being prescribed more frequently than glibenclamide (6976 vs 6789 person‐years), glimepiride induced fewer episodes of hypoglycaemia (6 vs 38 episodes); one episode occurred with a combination of the two preparations. The incidence of severe hypoglycaemia was 0.86/1000 person‐years for glimepiride and 5.6/1000 person‐years for glibenclamide. The characteristics of the 45 patients who presented with sulphonylurea‐associated hypoglycaemia were as follows: mean age 79 years (95% CI 75.2; 82.6); glycosylated haemoglobin 5.4% (95% CI 5.1; 5.7); impaired renal function in 62%. Conclusions In people with type 2 diabetes, glimepiride was associated with fewer episodes of severe hypoglycaemia than glibenclamide in routine clinical use. However, severe hypoglycaemia did occur with glimepiride and may be minimised if treatment targets are determined on an individual basis. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- Practicality and accuracy of prehospital rapid venous blood glucose determinationThe American Journal of Emergency Medicine, 2000
- Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal manExperimental and Clinical Endocrinology & Diabetes, 1999
- The Use of Sulphonylureas in the ElderlyDrugs & Aging, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The Effects of Acute Exercise on Metabolic Control in Type II Diabetic Patients Treated with Glimepiride or GlibenclamideHormone and Metabolic Research, 1996
- Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative StudyHormone and Metabolic Research, 1996
- Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor I. Binding characteristicsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1994
- Schätzung der Diabeteshäufigkeit in der Bundesrepublik Deutschland anhand von Krankenkassendaten: Sekundärdatenanalyse einer repräsentativen Stichprobe AOK-Versicherter der Stadt DortmundDeutsche Medizinische Wochenschrift (1946), 1992
- Relationship between lactate dehydrogenase and myeloperoxidase levels in human gingival crevicular fluid and clinical and microbial measurementsJournal of Clinical Periodontology, 1988
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976